VRCA — Verrica Pharmaceuticals Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1660334 ·
Last close
$3.14
Market Cap
$53.94M
52W High
$9.82
52W Low
$2.77
ADV30
60,234
Next earnings
2026-11-12
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 6,914,000 | 5,766,000 | -12,167,000 | -12,407,000 | 39,861,000 | 14,394,000 | 45,835,000 |
| Jun 2026 | 5,862,000 | 4,984,000 | -11,399,000 | -13,153,000 | 36,017,000 | 11,198,000 | 31,710,000 |
| Mar 2026 | 5,023,000 | 4,134,000 | -9,715,000 | -9,682,000 | 38,786,000 | 20,600,000 | 22,731,000 |
| Dec 2025 | 5,092,000 | 3,691,000 | -6,946,000 | -8,074,000 | 47,131,000 | 30,147,000 | 22,388,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-13,347,000
Investing CF
$0
Financing CF
$9,411,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.67
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-347,748,000
Inventory
$2,712,000
Receivables
$11,090,000
ST Investments
—
EBIT TTM
$-27,451,000
Pretax Income TTM
$-31,183,000
Interest Exp TTM
$3,732,000
Analysts
6
Yahoo Snapshot (yfinance, live)
Total Revenue
$22,891,000
EBITDA
$-39,729,000
Free Cash Flow
$-9,037,125
Enterprise Value
$73,087,888
Total Cash
$14,394,000
Total Debt
$11,636,000
Shares Out
17,178,786
Trailing EPS
$-2.30
Book Value
$-0.28
ROE
—
ROA
-62.3%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 35,577,000 | -11,939,000 | -17,886,000 | 47,131,000 | 22,388,000 | 24,743,000 | -17,627,000 |
| Dec 2024 | 7,566,000 | -65,836,000 | -76,579,000 | 54,134,000 | 63,994,000 | -9,860,000 | -60,927,000 |
| Dec 2023 | 5,124,000 | -63,222,000 | -66,995,000 | 81,597,000 | 61,834,000 | 19,763,000 | -38,577,000 |
| Dec 2022 | 9,032,000 | -21,296,000 | -24,487,000 | 44,721,000 | 4,688,000 | 40,033,000 | -18,650,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$30,321,000
NetIncome TTM
$-31,183,000
OpCashFlow TTM
—
Assets (Latest)
$36,017,000
Forward EPS
$-1.36
Max Pain — expiry 2027-03-19 (volume-derived — Yahoo OI feed degraded)
max pain strike: $4.00 · spot: $2.86 · call volume: 645 · put volume: 13
Expected Move to 2027-03-19:
±$2.19
(76.71%) —
implied range
$0.67 –
$5.05
· ATM straddle on $4.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| INCR | Intercure Ltd. | $54.16M | $3.61 | — |
| HRTX | HERON THERAPEUTICS, INC. /DE/ | $53.70M | $0.28 | — |
| XBIT | XBiotech Inc. | $54.27M | $1.78 | — |
| QUCY | Quantum Cyber N.V. | $54.38M | $0.62 | — |
| IBO | IMPACT BIOMEDICAL INC. | $53.31M | $6.17 | — |
News headlines (Yahoo Finance, 1h cache)
Verrica (VRCA) Q3 2026 Earnings Call Transcript
2026-11-13 16:30 · Yahoo
Verrica Pharmaceuticals Q3 Earnings Call Highlights
2026-11-13 06:14 · Yahoo
Verrica Pharmaceuticals Reports Third Quarter 2026 Financial Results
2026-11-12 21:16 · Yahoo
Verrica Pharmaceuticals to Participate in the Jefferies Global Healthcare Conference in London
2026-11-10 13:00 · Yahoo
Verrica Pharmaceuticals to Report Third Quarter 2026 Financial Results and Provide a Corporate Update on November 12, 2026
2026-11-05 13:00 · Yahoo
Verrica Pharmaceuticals Announces Achievement of Milestones Unlocking Access to the Full $27.5 Million of Non-Dilutive Growth Capital Under Credit Facility
2026-10-22 12:00 · Yahoo
Verrica Pharmaceuticals to Present New YCANTH® Data Analysis at Two Upcoming Dermatology Conferences
2026-09-30 12:00 · Yahoo
Verrica Pharmaceuticals to Present YCANTH® and VP-315 Data at Two Upcoming Dermatology Conferences
2026-09-10 12:05 · Yahoo
Verrica Pharmaceuticals to Participate in the H.C. Wainwright 28th Annual Global Investment Conference
2026-09-08 12:00 · Yahoo
Verrica completes enrolment in Phase III trial of Ycanth
2026-08-28 10:47 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.